Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.


Company website:http://www.alexionpharm.com

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

More info:http://finance.yahoo.com/q/pr?s=ALXN


ALXN - Alexion Pharmaceuticals Inc


Country: United States
Currency: USD
Margin: 10%
Is shortable: Yes


Trading hours:
SundayMondayTuesdayWednesdayThursdayFridaySaturday
Market is closed16:30 - 22:5916:30 - 22:5916:30 - 22:5916:30 - 22:5916:30 - 22:59Market is closed

Interest (annually):
Long positionShort position
–4.25% -1.75%

Interest Accrual

Temporary margin requirements due to upcoming corporate events:

Margin Calendar